Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Moderna CEO sees COVID shot being used for teens within weeks, Reuters says » 13:29
10/27/21
10/27
13:29
10/27/21
13:29
MRNA

Moderna

$346.67 /

+0.86 (+0.25%)

Moderna CEO Staphane…

Moderna CEO Staphane Bancel said he believes the drugmaker's COVID-19 vaccine will be authorized for 12- to 17-year-olds by the U.S. Food and Drug Administration in the next few weeks, Reuters' Carl O'Donnell reports, citing comments by Bancel. Moderna expects to apply for separate U.S. regulatory clearance in children ages six through 11 "very soon" and is hopeful that age group could start getting vaccinations by year end. Reference Link

ShowHide Related Items >><<
MRNA Moderna
$346.67 /

+0.86 (+0.25%)

MRNA Moderna
$346.67 /

+0.86 (+0.25%)

10/25/21 Piper Sandler
Piper reiterates $445 target on Moderna after 'positive' child vaccine data
10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
Moderna initiated with a Sell at Deutsche Bank
10/15/21
Fly Intel: Top five analyst upgrades
MRNA Moderna
$346.67 /

+0.86 (+0.25%)

MRNA Moderna
$346.67 /

+0.86 (+0.25%)

MRNA Moderna
$346.67 /

+0.86 (+0.25%)

MRNA Moderna
$346.67 /

+0.86 (+0.25%)

Conference/Events
Hanson Wade to hold a virtual summit » 09:10
10/27/21
10/27
09:10
10/27/21
09:10
PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

, JNJ

Johnson & Johnson

$165.77 /

+1.66 (+1.01%)

, AMGN

Amgen

$208.61 /

+1.09 (+0.53%)

, GSK

GlaxoSmithKline

$40.18 /

+0.375 (+0.94%)

, BMY

Bristol-Myers

$58.24 /

+0.47 (+0.81%)

, AZN

AstraZeneca

$62.29 /

+0.54 (+0.87%)

, LLY

Eli Lilly

$248.43 /

+3.26 (+1.33%)

, SNY

Sanofi

$49.98 /

+0.125 (+0.25%)

, BAYRY

Bayer

$14.20 /

+0.04 (+0.28%)

, KYMR

Kymera Therapeutics

$56.41 /

+1.19 (+2.16%)

, ARVN

Arvinas

$85.13 /

+0.29 (+0.34%)

, CCCC

C4 Therapeutics

$44.85 /

+0.65 (+1.47%)

, GLUE

Monte Rosa Therapeutics

$25.33 /

+2.91 (+12.98%)

, NRIX

Nurix Therapeutics

$28.77 /

+0.58 (+2.06%)

, FHTX

Foghorn Therapeutics

$12.70 /

+0.235 (+1.89%)

, NVS

Novartis

$84.84 /

+1.49 (+1.79%)

4th Targeted Protein…

4th Targeted Protein Degradation Virtual Summit to be held on October 26-29.Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NRIX Nurix Therapeutics
$28.77 /

+0.58 (+2.06%)

LLY Eli Lilly
$248.43 /

+3.26 (+1.33%)

KYMR Kymera Therapeutics
$56.41 /

+1.19 (+2.16%)

JNJ Johnson & Johnson
$165.77 /

+1.66 (+1.01%)

GSK GlaxoSmithKline
$40.18 /

+0.375 (+0.94%)

GLUE Monte Rosa Therapeutics
$25.33 /

+2.91 (+12.98%)

FHTX Foghorn Therapeutics
$12.70 /

+0.235 (+1.89%)

CCCC C4 Therapeutics
$44.85 /

+0.65 (+1.47%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

ARVN Arvinas
$85.13 /

+0.29 (+0.34%)

AMGN Amgen
$208.61 /

+1.09 (+0.53%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
JNJ Johnson & Johnson
$165.77 /

+1.66 (+1.01%)

10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
AMGN Amgen
$208.61 /

+1.09 (+0.53%)

10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/21/21 Oppenheimer
Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
GSK GlaxoSmithKline
$40.18 /

+0.375 (+0.94%)

10/18/21 Berenberg
GlaxoSmithKline price target lowered to 1,540 GBp from 1,625 GBp at Berenberg
10/07/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,555 GBp at Morgan Stanley
10/07/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,555 GBp at Morgan Stanley
10/04/21 Alliance Global Partners
Achieve Life Sciences initiated with a Buy at Alliance Global Partners
BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
10/25/21 SVB Leerink
Potential Bristol takeover of Aurinia makes strategic sense, says SVB Leerink
10/25/21 Citi
Bristol-Myers report of Aurinia approach 'looks credible,' says Citi
10/12/21 Morgan Stanley
Bristol-Myers price target lowered to $66 from $71 at Morgan Stanley
AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

09:01 Today SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
LLY Eli Lilly
$248.43 /

+3.26 (+1.33%)

06:39 Today Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
09/27/21 SVB Leerink
Sanofi upgraded to Outperform from Market Perform at SVB Leerink
BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

10/21/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
KYMR Kymera Therapeutics
$56.41 /

+1.19 (+2.16%)

10/13/21 Brookline
Kymera Therapeutics initiated with Buy, $80 target at Brookline
10/12/21 Brookline
Kymera Therapeutics initiated with a Buy at Brookline
09/30/21 B. Riley
Kymera Therapeutics initiated with Neutral on valuation at B. Riley
09/30/21 B. Riley
Kymera Therapeutics initiated with a Neutral at B. Riley
ARVN Arvinas
$85.13 /

+0.29 (+0.34%)

10/20/21 Stifel
Success of Radius' elacestrant lowers risk for Arvinas' ARV-471, says Stifel
10/14/21 SVB Leerink
Arvinas initiated with an Outperform at SVB Leerink
09/29/21 Stifel
Arvinas initiated with a Buy at Stifel
09/09/21 BofA
Arvinas initiated with a Buy at BofA
CCCC C4 Therapeutics
$44.85 /

+0.65 (+1.47%)

10/14/21 SVB Leerink
C4 Therapeutics initiated with a Market Perform at SVB Leerink
09/29/21 Stifel
C4 Therapeutics initiated with a Hold at Stifel
06/24/21 Brookline
C4 Therapeutics initiated with a Buy at Brookline
06/22/21 BMO Capital
C4 Therapeutics price target lowered to $53 from $55 at BMO Capital
GLUE Monte Rosa Therapeutics
$25.33 /

+2.91 (+12.98%)

10/14/21 SVB Leerink
Monte Rosa Therapeutics initiated with a Market Perform at SVB Leerink
07/19/21 JPMorgan
Monte Rosa Therapeutics initiated with an Overweight at JPMorgan
07/19/21 Guggenheim
Monte Rosa Therapeutics initiated with a Buy at Guggenheim
07/19/21 Piper Sandler
Monte Rosa Therapeutics initiated with an Overweight at Piper Sandler
NRIX Nurix Therapeutics
$28.77 /

+0.58 (+2.06%)

10/14/21 SVB Leerink
Nurix Therapeutics initiated with an Outperform at SVB Leerink
06/03/21 Baird
Nurix Therapeutics transferred with Outperform at Baird
04/30/21
Fly Intel: Top five analyst initiations
04/30/21 RBC Capital
Nurix Therapeutics initiated with an Outperform at RBC Capital
FHTX Foghorn Therapeutics
$12.70 /

+0.235 (+1.89%)

11/17/20 Morgan Stanley
Foghorn Therapeutics initiated with an Overweight at Morgan Stanley
11/17/20 Wedbush
Wedbush bullish on Foghorn Therapeutics, initiates with an Outperform
11/17/20 Wedbush
Foghorn Therapeutics initiated with an Outperform at Wedbush
11/17/20 Cowen
Foghorn Therapeutics initiated with an Outperform at Cowen
NVS Novartis
$84.84 /

+1.49 (+1.79%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

NRIX Nurix Therapeutics
$28.77 /

+0.58 (+2.06%)

LLY Eli Lilly
$248.43 /

+3.26 (+1.33%)

KYMR Kymera Therapeutics
$56.41 /

+1.19 (+2.16%)

JNJ Johnson & Johnson
$165.77 /

+1.66 (+1.01%)

GSK GlaxoSmithKline
$40.18 /

+0.375 (+0.94%)

GLUE Monte Rosa Therapeutics
$25.33 /

+2.91 (+12.98%)

CCCC C4 Therapeutics
$44.85 /

+0.65 (+1.47%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

ARVN Arvinas
$85.13 /

+0.29 (+0.34%)

AMGN Amgen
$208.61 /

+1.09 (+0.53%)

  • 01
    Jul
  • 24
    Jun
  • 17
    Jun
  • 05
    Mar
  • 16
    Dec
SNY Sanofi
$49.98 /

+0.125 (+0.25%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

LLY Eli Lilly
$248.43 /

+3.26 (+1.33%)

JNJ Johnson & Johnson
$165.77 /

+1.66 (+1.01%)

GSK GlaxoSmithKline
$40.18 /

+0.375 (+0.94%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

SNY Sanofi
$49.98 /

+0.125 (+0.25%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

LLY Eli Lilly
$248.43 /

+3.26 (+1.33%)

KYMR Kymera Therapeutics
$56.41 /

+1.19 (+2.16%)

JNJ Johnson & Johnson
$165.77 /

+1.66 (+1.01%)

GSK GlaxoSmithKline
$40.18 /

+0.375 (+0.94%)

GLUE Monte Rosa Therapeutics
$25.33 /

+2.91 (+12.98%)

CCCC C4 Therapeutics
$44.85 /

+0.65 (+1.47%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

BAYRY Bayer
$14.20 /

+0.04 (+0.28%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

AMGN Amgen
$208.61 /

+1.09 (+0.53%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

NVS Novartis
$84.84 /

+1.49 (+1.79%)

LLY Eli Lilly
$248.43 /

+3.26 (+1.33%)

KYMR Kymera Therapeutics
$56.41 /

+1.19 (+2.16%)

JNJ Johnson & Johnson
$165.77 /

+1.66 (+1.01%)

GSK GlaxoSmithKline
$40.18 /

+0.375 (+0.94%)

FHTX Foghorn Therapeutics
$12.70 /

+0.235 (+1.89%)

BMY Bristol-Myers
$58.24 /

+0.47 (+0.81%)

AZN AstraZeneca
$62.29 /

+0.54 (+0.87%)

AMGN Amgen
$208.61 /

+1.09 (+0.53%)

Yesterday
Hot Stocks
Pfizer, BioNTech confirm FDA panel supports EUA for COVID vaccine in children » 18:20
10/26/21
10/26
18:20
10/26/21
18:20
PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

, BNTX

BioNTech

$292.41 /

-2.63 (-0.89%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced that the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization for the companies' COVID-19 vaccine in children 5 to less than12 years of age. VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy. The committee reviewed the totality of scientific evidence shared by the companies, including results from a Phase 2/3 randomized, controlled trial that included ~4,500 children 5 to less than12 years of age. Participants in this age group received a two-dose regimen of 10-microgram doses administered 21 days apart, one-third of the 30-microgram dose used for people 12 years and older. This dose level was carefully selected for use in the trial based on safety, tolerability and immunogenicity data evaluated as part of a dose-ranging study. The Phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in participants without prior SARS-CoV-2 infection, measured from 7 days after the second dose. The Data Monitoring Committee for the study has reviewed the data and has not identified any serious safety concerns related to the vaccine. "We appreciated the opportunity to present our clinical data demonstrating the safety and high efficacy of our COVID-19 vaccine in children 5 to under 12 years of age," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. "COVID-19 is an ongoing threat for the more than 28 million young children in this age group in the U.S., as they remain at risk for this infection. About 10% of all weekly U.S. cases occur in children 5 to under 12 years of age with a potential risk of complications. In addition, immunizing children will help to get us closer to herd immunity, with the potential to stem the pandemic sooner. We thank the FDA advisory committee for their review and positive recommendation in support of Emergency Use Authorization to help protect this young population."

ShowHide Related Items >><<
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

Hot Stocks
Trillium shareholders approve acquisition by Pfizer subsidiary » 17:16
10/26/21
10/26
17:16
10/26/21
17:16
TRIL

Trillium Therapeutics

$17.97 /

+0.055 (+0.31%)

, PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

Trillium Therapeutics…

Trillium Therapeutics (TRIL) announced that its securityholders approved a statutory arrangement with PF Argentum, a wholly-owned, indirect subsidiary of Pfizer (PFE) at the special meeting of Trillium securityholders. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates. The arrangement is subject to court and regulatory approvals and clearances, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in Q4 of 2021 or the first half of 2022.

ShowHide Related Items >><<
TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

08/24/21 Craig-Hallum
Trillium Therapeutics downgraded to Hold at Craig-Hallum
08/24/21 Craig-Hallum
Trillium Therapeutics downgraded to Hold from Buy at Craig-Hallum
08/24/21 JMP Securities
Trillium downgraded to Market Perform from Outperform at JMP Securities
08/23/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

Hot Stocks
FDA panel votes in support of Pfizer-BioNTech vaccine for kids aged 5-11 » 16:19
10/26/21
10/26
16:19
10/26/21
16:19
PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

, BNTX

BioNTech

$292.41 /

-2.63 (-0.89%)

An FDA Advisory Committee…

An FDA Advisory Committee voted 17 yes to 0 no with 1 abstention that the totality of scientific evidence available supports the benefits of the Pfizer (PFE) and BioNTech (BNTX) COVID vaccine when administered as a 2-dose series outweigh its risks for use in children 5-11 years of age.

ShowHide Related Items >><<
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

Hot Stocks
Moderna reports first dosing in Phase 3 study of mRNA CMV vaccine » 14:39
10/26/21
10/26
14:39
10/26/21
14:39
MRNA

Moderna

$344.38 /

-5.32 (-1.52%)

Moderna announced the…

Moderna announced the first participant has been dosed in the Phase 3 pivotal registration study of mRNA-1647, the company's cytomegalovirus, or CMV, vaccine candidate. The Phase 3 study, known as CMVictory, will evaluate the safety and efficacy of mRNA-1647 against primary CMV infection in women ages 16-40 years. The company will seek to enroll approximately 8,000 participants in the study, including 6,900 women of childbearing age, from approximately 150 sites globally, beginning in the U.S.

ShowHide Related Items >><<
MRNA Moderna
$344.38 /

-5.32 (-1.52%)

MRNA Moderna
$344.38 /

-5.32 (-1.52%)

10/25/21 Piper Sandler
Piper reiterates $445 target on Moderna after 'positive' child vaccine data
10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
Moderna initiated with a Sell at Deutsche Bank
10/15/21
Fly Intel: Top five analyst upgrades
MRNA Moderna
$344.38 /

-5.32 (-1.52%)

MRNA Moderna
$344.38 /

-5.32 (-1.52%)

MRNA Moderna
$344.38 /

-5.32 (-1.52%)

MRNA Moderna
$344.38 /

-5.32 (-1.52%)

Hot Stocks
Moderna announces Swissmedic authorizes booster dose of Covid-19 vaccine » 09:45
10/26/21
10/26
09:45
10/26/21
09:45
MRNA

Moderna

$351.00 /

+1.3 (+0.37%)

Moderna announced…

Moderna announced Swissmedic has authorized a booster dose of Spikevax, the company's vaccine against COVID-19, at the 50 microgram dose level in particularly vulnerable individuals 12 years of age and older, at least six months after completion of the primary series. Swissmedic also approved a third dose of Spikevax at the 100 microgram dose level for people with a weakened immune system at least 28 days after the second dose. "We thank Swissmedic for their review and decision. This approval is supported by clinical evidence that a 50 microgram booster dose induces a strong immune response against COVID-19. We also appreciate their approval of a third dose of Spikevax for those with weakened immune systems," said Stephane Bancel, CEO of Moderna. "We believe that mRNA vaccines are well positioned to adapt to the evolving epidemiology of SARS-CoV-2. We are grateful for the opportunity to provide individuals in Switzerland with another layer of protection."

ShowHide Related Items >><<
MRNA Moderna
$351.00 /

+1.3 (+0.37%)

MRNA Moderna
$351.00 /

+1.3 (+0.37%)

10/25/21 Piper Sandler
Piper reiterates $445 target on Moderna after 'positive' child vaccine data
10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
Moderna initiated with a Sell at Deutsche Bank
10/15/21
Fly Intel: Top five analyst upgrades
MRNA Moderna
$351.00 /

+1.3 (+0.37%)

MRNA Moderna
$351.00 /

+1.3 (+0.37%)

MRNA Moderna
$351.00 /

+1.3 (+0.37%)

MRNA Moderna
$351.00 /

+1.3 (+0.37%)

Conference/Events
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting » 08:25
10/26/21
10/26
08:25
10/26/21
08:25
PFE

Pfizer

$43.16 /

+ (+0.00%)

, BNTX

BioNTech

$295.01 /

+16.63 (+5.97%)

The Committee discusses a…

The Committee discusses a request to amend Pfizer-BioNTech's Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age in a virtual meeting to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

PFE Pfizer
$43.16 /

+ (+0.00%)

Hot Stocks
BioNTech to initiate construction of mRNA vaccine facility in Africa in mid-2022 » 08:12
10/26/21
10/26
08:12
10/26/21
08:12
BNTX

BioNTech

$295.01 /

+16.63 (+5.97%)

BioNTech announced that…

BioNTech announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This is the next step in BioNTech's efforts to implement sustainable end-to-end vaccine supply solutions on the African continent. The decision is the result of a meeting between Rwanda's Minister of Health, Dr Daniel M. Ngamije, Senegal's Minister of Foreign Affairs Aissata Tall Sall, Ugur Sahin, M.D.,CEO and Co-Founder of BioNTech and Sierk Poetting, COO of BioNTech as well as Dr Sabin Nsanzimana, Director-General of Rwanda Biomedical Centre and Dr Amadou Alpha Sall, Directeur-General of Institut Pasteur de Dakar in Kigali, Rwanda. The meeting occurred upon the invitation of the kENUP Foundation and took place as a side-event of the Second Ministerial Meeting of the African Union and the European Union and resulted in a Memorandum of Understanding. This comes after the parties signed a Joint Communique at a previous meeting in Berlin on August 27, 2021. The parties agree to jointly establish end-to-end manufacturing capacities for mRNA-based vaccines in Africa starting immediately. BioNTech has finalized the construction plans and ordered the assets, which will be delivered by mid-2022. The new manufacturing facility could become the first node in a decentralized and robust African end-to-end manufacturing network enabling an annual manufacturing capacity of several hundreds of million mRNA vaccine doses. BioNTech plans to develop and implement a scalable construction network based on the expertise and learnings from the ramp-up of the Company's production facility in Marburg. To enable an expedient set-up of production capacities according to GMP standards, BioNTech will start with the construction and validation of a first production line enabling the manufacturing of drug product for about 50 million of e.g. COVID-19 vaccine doses per year, once fully operational. The capacity will be increased sequentially by adding further manufacturing lines and sites to the manufacturing network on the continent, supporting the production of several hundreds of millions of mRNA vaccine doses. BioNTech will initially staff, own and operate the facility to support the safe and rapid initiation of the production of mRNA-based vaccine doses. BioNTech plans to transfer manufacturing capacities and the know-how to local partners. Therefore, BioNTech, the Rwanda Development Board and Institut Pasteur de Dakar in Senegal agreed to swiftly build-up the required human resources capacity and systems so that the partners can take over ownership and operational duties. In parallel, the Republic of Rwanda and the Institut Pasteur de Dakar have committed themselves to scale-up fill and finish capacities to complete the local end-to-end manufacturing process. In addition, BioNTech is in discussions about an expansion of the current partnership with Cape Town-based vaccine manufacturer Biovac, which is part of the Pfizer-BioNTech COVID-19 vaccine manufaturing network.

ShowHide Related Items >><<
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

Hot Stocks
Moderna enters MoU to make 110M COVID-19 vaccine doses available for Africa » 05:28
10/26/21
10/26
05:28
10/26/21
05:28
MRNA

Moderna

$349.71 /

+23.11 (+7.08%)

Moderna announced a new…

Moderna announced a new memorandum of understanding, or MoU, to make up to 110M doses of the Moderna COVID-19 vaccine available to the African Union. The company is prepared to deliver the first 15M doses in Q4, 35M doses in Q1 of 2022, and up to 60M doses in Q2 of 2022. All doses are offered at Moderna's lowest tiered price. The company is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, in parallel to building an mRNA vaccine manufacturing facility in Africa. This new MoU would be in addition to Moderna's agreement with COVAX to supply up to 500M doses of its COVID-19 vaccine from Q4 of 2021 through 2022. Additionally, the company recently announced an investment of up to $500M to plan to build a mRNA facility in Africa with the goal of producing up to 500M doses of vaccines at the 50 microgram dose level each year.

ShowHide Related Items >><<
MRNA Moderna
$349.71 /

+23.11 (+7.08%)

MRNA Moderna
$349.71 /

+23.11 (+7.08%)

10/25/21 Piper Sandler
Piper reiterates $445 target on Moderna after 'positive' child vaccine data
10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
Moderna initiated with a Sell at Deutsche Bank
10/15/21
Fly Intel: Top five analyst upgrades
MRNA Moderna
$349.71 /

+23.11 (+7.08%)

MRNA Moderna
$349.71 /

+23.11 (+7.08%)

MRNA Moderna
$349.71 /

+23.11 (+7.08%)

MRNA Moderna
$349.71 /

+23.11 (+7.08%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.